<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112694</url>
  </required_header>
  <id_info>
    <org_study_id>A-US-52030-364</org_study_id>
    <nct_id>NCT03112694</nct_id>
  </id_info>
  <brief_title>Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors</brief_title>
  <official_title>A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how people with neuroendocrine tumors respond to
      treatment with lanreotide after having received treatment with octreotide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Actual">November 2, 2017</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>Evaluated as responsive disease (i.e., complete response, partial response), stable disease or progressive disease at the last tumor assessment while on treatment with lanreotide (based on tumor imaging, symptoms, biomarker(s) and/or clinical judgement)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, after treatment with octreotide</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>For evaluating progression-free survival events will include radiographic progression per investigator, biomarker progression per investigator, symptom progression per investigator, and death. Adverse events (AEs) will not be considered as an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response to lanreotide, after treatment with octreotide</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>For evaluating duration of response events will include radiographic progression per investigator, biomarker progression per investigator, symptom progression per investigator, AEs, and death. Open ended responses will be reviewed during the analysis and determined to be an eligible &quot;event&quot; or not at that time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment with octreotide and duration of treatment with lanreotide</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>Duration of octreotide treatment assessed as time from start of octreotide treatment to stop of octreotide treatment. Duration of lanreotide treatment assessed as time from lanreotide initiation to end of lanreotide treatment (censored at the date of last administration (+lanreotide frequency) for patients who had ongoing lanreotide treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Adverse Events</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>Summarized separately during treatment with octreotide and during treatment with lanreotide, as available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for switching from octreotide to lanreotide</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>Summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of 5-hydroxyindoleacetic acid (5-HIAA) (urine test or blood test) before treatment with octreotide, during treatment with octreotide and during treatment with lanreotide, as available</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>Summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Chromogranin A (CgA) before treatment with octreotide, during treatment with octreotide and during treatment with lanreotide, as available</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>Summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of symptoms (i.e., flushing, diarrhea, dyspnea, abdominal pain, edema, nausea) before treatment with octreotide, during treatment with octreotide, and during treatment with lanreotide, as available</measure>
    <time_frame>4 months (data collection duration)</time_frame>
    <description>Proportion of patients reporting each symptom</description>
  </secondary_outcome>
  <enrollment type="Actual">93</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitals and clinics
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females age 18 years or older at time of locally advanced or metastatic
             diagnosis

          -  Patients with a confirmed diagnosis of locally advanced or metastatic
             Gastroenteropancreatic neuroendocrine tumour (GEP-NET)

          -  Patients who switched treatment from long acting octreotide LAR to lanreotide, where
             both treatments were received for the treatment of locally advanced or metastatic
             GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days
             before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii.
             Treatment with lanreotide monotherapy for at least 90-days after treatment with long
             acting octreotide monotherapy (rescue SSA# use permitted)

        Exclusion Criteria:

          -  Patients with other malignant disease

          -  Patients who participated in a concomitant clinical trial related to treatment of
             GEP-NET

          -  Patients being treated with a Somatostatin analogue (SSA) in combination with other
             NET treatments excluding rescue SSA#

          -  Patients who received other primary treatment (e.g., targeted therapy, chemotherapy)
             for GEP-NET during the interval between octreotide and lanreotide

          -  Patients with NET familial genetic syndrome (i.e., MEN1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beloo Mirakhur, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Transitional Research</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

